BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

Impact · against what's priced in

The Q3 earnings beat for BMY is a positive development but lacks a pre-existing valuation framework to measure against, while the news is immaterial for MRK. For BMY, the shift toward its Growth Portfolio suggests a successful mitigation of patent cliff risks.

MRK+0.00

Doesn't touch the price's assumptions

In context

The article mentions MRK's collaboration on Reblozyl, but the general positive sentiment around BMY's earnings does not impact the specific drivers of MRK's valuation, such as the mRNA vaccine or Keytruda's patent life.

What MRK's price assumes · Sep 11

• earnings▲2%
• healthcare
• biotech
• BMY
• MRK
• growth portfolio
• pharma
• revenue beat

Top 1 mover · tap to explore